sabrcapitalmanagement.com
Advisory Clients | SABR Capital Management
http://www.sabrcapitalmanagement.com/advisory-clients.html
SABR Capital Management is not a broker dealer nor registered investment advisor. SABR Capital Management services exclude any financially related transactions including activities related to securities transactions, capital raising or formation.
mvssolutions.com
MVS Solutions - The Technology Development Company - Medical, Chemistry, Life Sciences & Business
http://www.mvssolutions.com/clients.html
MVS Solutions has earned an excellent reputation for applying its business and technology know-how, problem-solving skills and experience to a diverse range of clients and industries. Our customers and clients include:. Universities and Research Centers. MVS has established a solid track record of successful engagements and projects. A sampling of our customer and client base includes the following companies:. BMWC Constructors, Inc. Brontes Technologies, Inc. Discovery Genomics, Inc. Gene Link, Inc.
ldmicro.missionir.com
MissionIR - LD Micro Conference June 7-9, 2016 Luxe Hotel Sunset Boulevard (Los Angeles)
http://www.ldmicro.missionir.com/wednesday.html
June 7-9, 2016. Luxe Hotel Sunset Boulevard (Los Angeles). The three-day LD Micro Invitational in Bel Air, California, features company presentations from more than 200 select high-potential small-cap companies spanning multiple industries. Institutional and retail investors in attendance also have access to numerous networking opportunities and social events to learn more about these companies. Tuesday, June 7th. Wednesday, June 8th. Thursday, June 9th. Entia, Inc. (ERGO). S&W Seed Company (SANW). Signa...
enhancedonlinenews.com
CEL-SCI Corporation Reports Third Quarter Fiscal Year 2015 Financial Results | EON: Enhanced Online News
http://www.enhancedonlinenews.com/news/eon/20150807005568/en
CEL-SCI Corporation Reports Third Quarter Fiscal Year 2015 Financial Results. August 07, 2015 04:30 PM Eastern Daylight Time. VIENNA, Va.- ( EON: Enhanced Online News. CEL-SCI Corporation (NYSE MKT: CVM). Today reported financial results for the quarter ended June 30, 2015. Recent key corporate and clinical developments include:. Reported record patient enrollment numbers in April with 31 patients, 26 patients in May and 25 patients in June in the Phase 3 head and neck cancer trial. CEL-SCI reported an o...
thecatalystcompany.com
Catalyst Marketing Communications
http://www.thecatalystcompany.com/testimonials.html
What our clients say. Cliff Reid, CEO Complete Genomics. Catalyst transformed our positioning from technology-driven to market-driven. The human only positioning they developed succinctly and powerfully defined our niche - and it is recognized as the biggest niche. The positioning gave our technology added credibility, and has given our services model long-term viability. Geoff Mackay, President and CEO Organogenesis. Geert Kersten, President and CEO Cel-Sci. Catalyst challenged our thinking, forced us t...
oep.com.tw
OEP友華生技- 合作夥伴
http://www.oep.com.tw/zh-tw/ams/business_3
地址 台北市復興南路一段368號7樓 電話 (02)2755-4881 電子郵件 oep@mail.oep.com.tw.
goalcapital.net
Our Clients - Goal Capital Inc.
http://goalcapital.net/our-clients
Goal Capital Inc. has worked with many publicly traded companies since its inception in 2007 including NYSE-Amex, TSX , TSX.V, OCTBB, and CNSX listed clients. Please see some of Goal Capital past and present clients. TORONTO MKT – IMV. OTC – IMMVF. NYSE MKT – GSV. TSXV – GSV. Seabridge Gold, Inc. Meadow Bay Gold Corp. TSX: APG – AMEX: AGT. Paramount Gold & Silver, a Company to Watch. Paramount orchestrates a golden revival at Sleeper. Interview with CEO of Meadow Bay Gold, Robert Dinning, April 2013.
laboratorio-italia.it
Interleuchine leucocitarie e lotta ai tumori, autorizzati trial clinici di fase 3 in Italia grazie a CEL-SCI - Laboratorio Italia
http://www.laboratorio-italia.it/interleuchine-leucocitarie-e-lotta-ai-tumori-autorizzati-trial-clinici-di-fase-3-in-italia-grazie-a-cel-sci-98046
Interleuchine leucocitarie e lotta ai tumori, autorizzati trial clinici di fase 3 in Italia grazie a CEL-SCI. CEL-SCI ha annunciato che l’Agenzia Italiana del Farmaco ( AIFA. Ha autorizzato la società ad avviare l’arruolamento dei pazienti per il suo trial clinico di fase 3 di prova della sua immunoterapia sperimentale Multikine. L’obiettivo dello studio è quello di dimostrare un miglioramento statisticamente significativo nella sopravvivenza complessiva dei pazienti arruolati che sono trattati con...
SOCIAL ENGAGEMENT